236 related articles for article (PubMed ID: 26828563)
1. Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan.
Urup T; Dahlrot RH; Grunnet K; Christensen IJ; Michaelsen SR; Toft A; Larsen VA; Broholm H; Kosteljanetz M; Hansen S; Poulsen HS; Lassen U
Acta Oncol; 2016; 55(4):418-22. PubMed ID: 26828563
[TBL] [Abstract][Full Text] [Related]
2. Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine.
Heiland DH; Masalha W; Franco P; Machein MR; Weyerbrock A
J Neurooncol; 2016 Feb; 126(3):567-75. PubMed ID: 26614518
[TBL] [Abstract][Full Text] [Related]
3. Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.
Shields LB; Shelton BJ; Shearer AJ; Chen L; Sun DA; Parsons S; Bourne TD; LaRocca R; Spalding AC
Radiat Oncol; 2015 Oct; 10():222. PubMed ID: 26520780
[TBL] [Abstract][Full Text] [Related]
4. Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients.
Jakobsen JN; Urup T; Grunnet K; Toft A; Johansen MD; Poulsen SH; Christensen IJ; Muhic A; Poulsen HS
J Neurooncol; 2018 Apr; 137(2):439-446. PubMed ID: 29330749
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy.
Møller S; Grunnet K; Hansen S; Schultz H; Holmberg M; Sorensen M; Poulsen HS; Lassen U
Acta Oncol; 2012 Jul; 51(6):797-804. PubMed ID: 22548369
[TBL] [Abstract][Full Text] [Related]
6. FLAIR-only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival.
Schaub C; Greschus S; Seifert M; Waha A; Blasius E; Rasch K; Landwehr C; Mack F; Schäfer N; Stuplich M; Kebir S; Vilz B; Scheffler B; Boström J; Simon M; Urbach H; Glas M; Herrlinger U
Oncology; 2013; 85(3):191-5. PubMed ID: 24008924
[TBL] [Abstract][Full Text] [Related]
7. Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials.
Ellingson BM; Harris RJ; Woodworth DC; Leu K; Zaw O; Mason WP; Sahebjam S; Abrey LE; Aftab DT; Schwab GM; Hessel C; Lai A; Nghiemphu PL; Pope WB; Wen PY; Cloughesy TF
Neuro Oncol; 2017 Jan; 19(1):89-98. PubMed ID: 27580889
[TBL] [Abstract][Full Text] [Related]
8. Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab.
Pope WB; Xia Q; Paton VE; Das A; Hambleton J; Kim HJ; Huo J; Brown MS; Goldin J; Cloughesy T
Neurology; 2011 Feb; 76(5):432-7. PubMed ID: 21282590
[TBL] [Abstract][Full Text] [Related]
9. A meta-analysis of bevacizumab alone and in combination with irinotecan in the treatment of patients with recurrent glioblastoma multiforme.
Zhang G; Huang S; Wang Z
J Clin Neurosci; 2012 Dec; 19(12):1636-40. PubMed ID: 23047061
[TBL] [Abstract][Full Text] [Related]
10. Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study.
Boxerman JL; Zhang Z; Safriel Y; Larvie M; Snyder BS; Jain R; Chi TL; Sorensen AG; Gilbert MR; Barboriak DP
Neuro Oncol; 2013 Jul; 15(7):945-54. PubMed ID: 23788270
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors in recurrent glioblastoma patients treated with bevacizumab.
Schaub C; Tichy J; Schäfer N; Franz K; Mack F; Mittelbronn M; Kebir S; Thiepold AL; Waha A; Filmann N; Banat M; Fimmers R; Steinbach JP; Herrlinger U; Rieger J; Glas M; Bähr O
J Neurooncol; 2016 Aug; 129(1):93-100. PubMed ID: 27193554
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab for Patients with Recurrent Multifocal Glioblastomas.
Burger MC; Breuer S; Cieplik HC; Harter PN; Franz K; Bähr O; Steinbach JP
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29156610
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study.
Hofland KF; Hansen S; Sorensen M; Engelholm S; Schultz HP; Muhic A; Grunnet K; Ask A; Costa JC; Kristiansen C; Thomsen C; Poulsen HS; Lassen U
Acta Oncol; 2014 Jul; 53(7):939-44. PubMed ID: 24456504
[TBL] [Abstract][Full Text] [Related]
14. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Brandes AA; Tosoni A; Basso U; Reni M; Valduga F; Monfardini S; Amistà P; Nicolardi L; Sotti G; Ermani M
J Clin Oncol; 2004 Dec; 22(23):4779-86. PubMed ID: 15570079
[TBL] [Abstract][Full Text] [Related]
15. Limited impact of prognostic factors in patients with recurrent glioblastoma multiforme treated with a bevacizumab-based regimen.
Tabouret E; Barrie M; Thiebaut A; Matta M; Boucard C; Autran D; Loundou A; Chinot O
J Neurooncol; 2013 Sep; 114(2):191-8. PubMed ID: 23756726
[TBL] [Abstract][Full Text] [Related]
16. The optimal regimen of bevacizumab for recurrent glioblastoma: does dose matter?
Blumenthal DT; Mendel L; Bokstein F
J Neurooncol; 2016 May; 127(3):493-502. PubMed ID: 26721244
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial.
Beije N; Kraan J; Taal W; van der Holt B; Oosterkamp HM; Walenkamp AM; Beerepoot L; Hanse M; van Linde ME; Otten A; Vernhout RM; de Vos FY; Gratama JW; Sleijfer S; van den Bent MJ
Br J Cancer; 2015 Jul; 113(2):226-31. PubMed ID: 26042933
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma.
Field KM; Simes J; Nowak AK; Cher L; Wheeler H; Hovey EJ; Brown CS; Barnes EH; Sawkins K; Livingstone A; Freilich R; Phal PM; Fitt G; ; Rosenthal MA
Neuro Oncol; 2015 Nov; 17(11):1504-13. PubMed ID: 26130744
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.
Reardon DA; Desjardins A; Peters KB; Gururangan S; Sampson JH; McLendon RE; Herndon JE; Bulusu A; Threatt S; Friedman AH; Vredenburgh JJ; Friedman HS
J Neurooncol; 2012 Mar; 107(1):155-64. PubMed ID: 21986722
[TBL] [Abstract][Full Text] [Related]
20. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma.
Kickingereder P; Wiestler B; Burth S; Wick A; Nowosielski M; Heiland S; Schlemmer HP; Wick W; Bendszus M; Radbruch A
Neuro Oncol; 2015 Aug; 17(8):1139-47. PubMed ID: 25754089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
